Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Publication Information:
      Asociacion Colombiana de Dermatologia y Cirugia Dermatologica, 2024.
    • Publication Date:
      2024
    • Abstract:
      Atopic dermatitis (AD) is a chronic inflammatory disease characterized by relapsing eczema and pruritus. Recently, dupilumab has shown to be safe and improve symptoms of moderate to severe AD in adolescents up to 52 weeks, however, very few Latin American patients were included, so comprehensive real-world data is needed. To our knowledge, there are no real-world studies published in this ethnicity regarding long-term treatment with Dupilumab for AD in adolescents.
    • ISSN:
      1657-0448
    • Accession Number:
      10.29176/2590843x.1743
    • Rights:
      CC BY NC SA
    • Accession Number:
      edsair.doi...........ca6cfb345721500a1ed8b01d78524bb7